Lenalidomide
FDA Approves Kyprolis As A Second-Line Treatment For Multiple Myeloma
| Saranya Palanisamy | | Jul 25, 2015 06:55 PM EDT |
Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone is approved by FDA for use in patients ailing from relapsed multiple myeloma that has received two to three prior therapies including treatment with bortezomib (Velcade, Millennium).
Advertisement
Subscribe to CHINATOPIX !
Sign up for our free weekly newsletter for the latest in-depth coverage!
EDITOR'S PICKS
-
Did the Trump administration just announce plans for a trade war with ‘hostile’ China and Russia?
-
US Senate passes Taiwan travel bill slammed by China
-
As Yan Sihong’s family grieves, here are other Chinese students who went missing abroad. Some have never been found
-
Beijing blasts Western critics who ‘smear China’ with the term sharp power
-
China Envoy Seeks to Defuse Tensions With U.S. as a Trade War Brews
-
Singapore's Deputy PM Provides Bitcoin Vote of Confidence Amid China's Blanket Bans
-
China warns investors over risks in overseas virtual currency trading
-
Chinese government most trustworthy: survey
-
Kashima Antlers On Course For Back-To-Back Titles
Advertisement
MOST POPULAR
Advertisement
LATEST NEWS
Zhou Yongkang: China's Former Security Chief Sentenced to Life in Prison
China's former Chief of the Ministry of Public Security, Zhou Yongkang, has been given a life sentence after he was found guilty of abusing his office, bribery and deliberately ... Full Article
Advertisement
TRENDING STORY
China Pork Prices Expected to Stabilize As The Supplies Recover
-
Elephone P9000 Smartphone is now on Sale on Amazon India
-
There's a Big Chance Cliffhangers Won't Still Be Resolved When Grey's Anatomy Season 13 Returns
-
Supreme Court Ruled on Samsung vs Apple Dispute for Patent Infringement
-
Microsoft Surface Pro 5 Rumors and Release Date: What is the Latest?
Advertisement
